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Case Report: Hypersensitivity Mediated ST-Elevation Myocardial Infarction
“Kounis Syndrome with Cronovich Phenomenon”
Jabour, J. DO, Cronovich, H. DO
Department of Emergency Medicine, Henry Ford Macomb Hospital, Clinton Twp, Michigan

Abstract
Introduction: ST elevation myocardial infarction in concurrence with angioedema, anaphylaxis,
hypersensitivity, or platelet activation is an event well published in literature known as KounisSyndrome. Classically, these events are linked by the administration of epinephrine either
intravenously or intramuscularly for the treatment of the acute immunologic response.
Case Report: This particular case is a 78 year old male with history of c1 esterase inhibitor
deficiency, angioedema, and hypertension presenting with angioedema. His symptoms started the
previous night and were managed in the ED with methylprednisolone, diphenhydramine, and
famotidine. The patient was intubated for airway protection and extubated about 24 hours later.
About 48 hours after symptom onset, the patient developed acute chest pain and STEMI. He
underwent PCI and stent placement after a 99.9% occlusion of the proximal LAD was identified.
Discussion: This case is unique because the patient did not receive epinephrine for the treatment of
his immune response, and the 48 hour latency of STEMI symptoms. This particular case is unlike
classic Kounis syndrome and suggests that ACS in the setting of acute immune response is
independent of epinephrine administration. It also postulates that latent mediators of immune
response and/or their degradation may play an important role in the development of ACS.
Conclusions: Kounis syndrome and this case in particular provide a novel area of study for the
pathophysiology, prevention, and treatment of ACS. In patients with a history of CAD presenting
with acute immune response, emergency providers should keep a high suspicion for the potential of
ACS and use epinephrine judiciously.

Introduction
• Kounis Syndrome is described as an acute hypersensitivity induced
STEMI or other ACS.
• Type I Kounis Syndrome variant refers to coronary artery vasospasm in
normal coronary arteries as a result of the acute release of inflammatory
mediators. (1)
• Type II Kounis Syndrome variant refers to either coronary artery
vasospasm or acute plaque rupture in known coronary atheromatous
disease. (2)
• Type III Kounis Syndrome variant refers to coronary stent restenosis or
repeat thrombosis as a result of inflammatory infiltration or induced by
inflammatory mediators. (3)
• Each variant may present along the spectrum of acute coronary syndrome
with or without troponin elevation.

Case Report
This case is a 78 year old male with history of c1 esterase inhibitor
deficiency, angioedema, and hypertension presenting with angioedema.
His symptoms started the previous night and were managed the
following morning in the ED with methylprednisolone,
diphenhydramine, and famotidine. The patient was intubated for airway
protection and extubated about 24 hours later. As an inpatient, the patient
received a dose of c1 esterase inhibitor. About 48 hours after symptom
onset, the patient developed acute chest pain and STEMI. He underwent
PCI and stent placement after a 99.9% occlusion of the proximal LAD
was identified. A 75% RCA stenosis was also identified during the
procedure. Following the procedure, an echocardiogram revealed an EF
of 21%. The patient underwent catheterization and stenting of the RCA
a month later after presenting with an episode of SVT. One day
following the procedure, repeat echocardiogram revealed an EF of 62%.

Pathophysiology
• Coronary thrombosis results from activated mast cells and their
mediators (histamine and bradykinin) acting on platelets expressing
similar IgE. The activated platelets undergo conformational change and
express glycoprotein 1b to bind VWf to the endothelial wall. Platelets
release proinflammatory and prothrombotic mediators (thromboxane
A2), and the coagulation cascade ensues. (4)
• Further, mast cells infiltrate preexisting coronary artery plaques and
reside in the lesions along with macrophages and T-cells. Once activated,
the release of pro-inflammatory mediators (histamine, leukotrienes,
prostaglandins, cytokines, proteases, tryptase) contribute to plaque
instability and rupture. (5)
• Plaque rupture and thrombosis of the coronary artery goes on to cause
ischemia and subsequent necrosis of the myocardium if perfusion is not
restored.

EKG

Discussion
• This patient’s presentation mostly closely aligns with type II Kounis
syndrome variant as evidenced by existing coronary artery disease in
the RCA during catheterization.
• This patient had a history of c1 esterase inhibitor deficiency and
received c1 esterase inhibitor prior to the STEMI. Patients receiving
c1 esterase inhibitor less than 6 hours between symptom onset and
reperfusion had significantly lower TnI serum levels postoperatively
compared to patients who did not receive c1 esterase inhibitor
therapy or therapy after greater than 6 hours (p< .05). This RCT
demonstrated the complement system as a significant contributor to
cardiac ischemic-reperfusion injury. (6)
• Kounis syndrome has also been linked to the administration of
epinephrine during the acute immune response. Classically, the
pathophysiology and literature suggest concurrent immune response
and STEMI symptoms. The patent did not receive epinephrine and
his STEMI symptoms started about 48 hours following the acute
immune response. This presentation suggests latent mediators of
immune response activation and/or their degradation as cause for
STEMI, and provides novel areas of study in pathophysiology,
treatment, and prevention of ACS. Lastly, the investigators of the
case suggest the name Cronovich phenomenon for latent STEMI in
the setting of acute immune response.

Conclusions
• In the setting of acute immune response, atheromatous mast cell
activation, vessel permeability leading to hypoperfusion, complement
activation, and systemic vasodilation reducing cardiac output all must be
considered in playing a role in ACS.
Figure 1 – 12 Lead EKG taken at the time of symptom onset. Sinus tachycardia with
significant ST-elevation visualized in anterior and lateral leads.

Therapeutic Intervention

• In patients with a history of CAD presenting with acute immune
response, all providers should keep a high suspicion for the potential of
ACS presenting acutely as Kounis Syndrome or latent as Kounis
Syndrome with Cronovich phenomenon.
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